Cargando…
Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System
PURPOSE: Standard-of-care therapies for metastatic renal cell carcinoma (mRCC) have greatly evolved. However, the availability of emerging options in global health care systems can vary. We sought to describe the integration and usage of systemic therapies for mRCC in Canada since 2011. METHODS: We...
Autores principales: | Cardenas, Luisa M., Ghosh, Sunita, Finelli, Antonio, Wood, Lori, Kollmannsberger, Christian, Basappa, Naveen, Graham, Jeffrey, Heng, Daniel, Bjarnason, Georg, Soulières, Denis, Bossé, Dominick, Castonguay, Vincent, Saleh, Ramy, Tanguay, Simon, Bhindi, Bimal, Breau, Rodney H., Pouliot, Frederic, Lalani, Aly-Khan A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681568/ https://www.ncbi.nlm.nih.gov/pubmed/37992270 http://dx.doi.org/10.1200/GO.23.00271 |
Ejemplares similares
-
Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System
por: Nguyen, Eric K., et al.
Publicado: (2022) -
Evaluating the impact of early identification of asymptomatic brain metastases in metastatic renal cell carcinoma
por: Parmar, Ambica, et al.
Publicado: (2022) -
Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review
por: Lalani, Aly-Khan A., et al.
Publicado: (2022) -
Management of complex renal cysts in Canada: results of a survey study
por: Couture, Félix, et al.
Publicado: (2020) -
Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts
por: Bossé, Dominick, et al.
Publicado: (2020)